Arcturus Therapeutics Holdings (ARCT) Change in Account Payables (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported Change in Account Payables of -$142000.0 for Q1 2026, up 86.01% on a YoY basis from -$76340.0 in Q1 2025, and up 89.43% quarter-over-quarter from -$1.3 million in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Change in Account Payables (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported Change in Account Payables for 9 years, with the latest figure at -$142000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 86.01% year-over-year to -$142000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (up 29.65% YoY), and the FY2025 full-year result was -$3.0 million, down 254.52% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$142000.0, up from -$1.3 million in the prior quarter.
- The five-year high for Change in Account Payables was $11.8 million in Q1 2023, with the low at -$12.7 million in Q4 2023.
- Historically, Change in Account Payables has averaged -$384470.6 across 5 years, with a median of -$1.0 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 569.28% — and 2023, when it surged 26890.91%.
- Arcturus Therapeutics Holdings' Change in Account Payables stood at -$8.4 million in 2022, then tumbled by 50.76% to -$12.7 million in 2023, then jumped by 76.94% to -$2.9 million in 2024, then jumped by 54.27% to -$1.3 million in 2025, then surged by 89.43% to -$142000.0 in 2026.
- The last three Change in Account Payables figures came in at -$142000.0 (Q1 2026), -$1.3 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | -142,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -142,000.00 |
| Mar 31, 2026 | -142,000.00 |
| Dec 31, 2025 | -1.34 Mn |
| Dec 31, 2025 | -1.34 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Jun 30, 2025 | 4.44 Mn |
| Jun 30, 2025 | 4.44 Mn |
| Mar 31, 2025 | -1.02 Mn |
| Mar 31, 2025 | -1.02 Mn |
| Dec 31, 2024 | -2.94 Mn |
| Dec 31, 2024 | -2.94 Mn |
| Sep 30, 2024 | -3.77 Mn |
| Sep 30, 2024 | -3.77 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | -12.74 Mn |
| Dec 31, 2023 | -12.74 Mn |